New research finds pathogenic connection between autoimmune disorders and cancer

July 22, 2014

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University (GW) researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22.

This paradigm shifting work shows that the very same inhibitors of apoptosis, or cell destruction, in tumors are also expressed in cells that produce . Henry Kaminski, M.D., chair of the Department of Neurology at the GW School of Medicine and Health Sciences (SMHS), as well as colleagues from the Roswell Park Cancer Institute, collaborated with Kusner's laboratory on this research. Together they discovered that survivin, an inhibitor of apoptosis, is also expressed in the , called lymphocytes, of patients with the autoimmune disease myasthenia gravis, but not in normal individuals. This was also the case in animal models of myasthenia gravis. Myasthenia gravis is a severe muscle disease that can lead to such weakness that patients must be placed on breathing machines.

"We found that humans with myasthenia gravis also express survivin in autoreactive lymphocytes," said Kusner, assistant research professor in the Department of Pharmacology and Physiology at SMHS. "We found these cells to be part of the dysfunction underlying the autoimmune disease."

Using a vaccine technique, the research team was able to eliminate the survivin-expressing cells and demonstrate improvement in the animal models with myasthenia gravis. Kusner's laboratory will continue to work to improve the inhibition of survivin as a treatment and one day bring survivin targeted treatment to patients.

"This study opens a new therapeutic approach for , as well as other ," said Kaminski. "Conventional therapies may improve the disease, but have numerous complications. This discovery may lead to a viable treatment option for the millions of American suffering from these disorders."

Explore further: Researchers halt autoimmune disease myasthenia gravis in mice

More information: The article, "Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study," is available at dx.plos.org/10.1371/journal.pone.0102231

Related Stories

Researchers halt autoimmune disease myasthenia gravis in mice

October 1, 2012

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response ...

Network of experts join forces to fight myasthenia gravis

July 22, 2014

Collaboration between research groups is key in tackling rare diseases such as auto-immune disease myasthenia gravis (MG). Indeed, the rarity of the disease means that it can be difficult to collect enough samples of blood ...

Auto-immune disease: The viral route is confirmed

December 19, 2012

Why would our immune system turn against our own cells? This is the question that the combined Inserm/CNRS/ Pierre and Marie Curie University/Association Institut de Myologie have strived to answer in their "Therapies for ...

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.